Biotech

All Articles

BMS trenches TIGIT, walking away from $200M bet on Agenus bispecific

.Bristol Myers Squibb is actually axing an additional large wager from the Caforio age, ending a pac...

Nuvation halts BET inhibitor after thinking about period 1 information

.After having a look at phase 1 data, Nuvation Biography has decided to halt work on its own one-tim...

' Scientific intuitiveness' led FDA experts to support Zevra's rare ailment med

.Zevra Therapeutics' unusual condition medication seems to become on the road to authorization this ...

Pfizer takes $230M hit after axing stopped working DMD gene treatment

.Pfizer's period 3 Duchenne muscle dystrophy (DMD) gene treatment breakdown has gone a $230 thousand...

AC Immune views 'landmark' possible in Alzheimer's medicine records

.After greater than two decades of work with neurodegenerative diseases, Swiss biotech AC Immune sys...

GSK drops ph. 2 HPV vaccine over lack of best-in-class prospective

.GSK has actually ditched a period 2 human papillomavirus (HPV) vaccine from its pipe after determin...

OS Treatments refiles $6M IPO to cash HER2 medicine, preclinical ADCs

.OS Therapies will provide on the NYSE American supply swap today via a $6.4 million IPO that the bi...

ALX's waning CD47 action price sends out inventory spiraling down

.ALX Oncology's period 2 stomach cancer response fee has weakened. After seeing its CD47 blocker eff...

Ionis axes eye health condition from aim ats of Roche-partnered possibility after records let down

.Another of Ionis Pharmaceuticals' key midphase readouts has fallen short of requirements, cuing the...

Biogen's CEO pointed out no dangerous handle 2023. He prepares to become daring

.While Biogen's pharma peers are actually searching for late-stage properties with little bit of thr...